361 related articles for article (PubMed ID: 17185787)
21. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS.
Teede HJ; Hutchison S; Zoungas S; Meyer C
Endocrine; 2006 Aug; 30(1):45-53. PubMed ID: 17185791
[TBL] [Abstract][Full Text] [Related]
22. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
[TBL] [Abstract][Full Text] [Related]
23. Insulin sensitizers in polycystic ovary syndrome.
Pasquali R; Gambineri A
Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
[TBL] [Abstract][Full Text] [Related]
24. Polycystic ovary syndrome and type 2 diabetes mellitus.
De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
[TBL] [Abstract][Full Text] [Related]
25. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome.
Mukherjee S; Shaikh N; Khavale S; Shinde G; Meherji P; Shah N; Maitra A
Eur J Endocrinol; 2009 May; 160(5):855-62. PubMed ID: 19211708
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
27. Study of the association of the T869C polymorphism of the transforming growth factor-β1 gene with polycystic ovary syndrome.
Park JH; Li L; Baek KH
Mol Med Rep; 2015 Sep; 12(3):4560-4565. PubMed ID: 26059110
[TBL] [Abstract][Full Text] [Related]
28. Insulin Resistance and Polycystic Ovary Syndrome.
Moghetti P
Curr Pharm Des; 2016; 22(36):5526-5534. PubMed ID: 27510482
[TBL] [Abstract][Full Text] [Related]
29. [Insulin resistance and polycystic ovary syndrome].
Dewailly D; Cortet-Rudelli C; Nobels F; Henric B; Longelin C; Fossati P
Ann Endocrinol (Paris); 1992; 53(1):1-7. PubMed ID: 1444176
[TBL] [Abstract][Full Text] [Related]
30. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M
Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143
[TBL] [Abstract][Full Text] [Related]
31. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study.
Hosseinpanah F; Barzin M; Keihani S; Ramezani Tehrani F; Azizi F
Clin Endocrinol (Oxf); 2014 Jul; 81(1):93-9. PubMed ID: 24428207
[TBL] [Abstract][Full Text] [Related]
32. Obstructive sleep apnoea and polycystic ovary syndrome: A comprehensive review of clinical interactions and underlying pathophysiology.
Kahal H; Kyrou I; Tahrani AA; Randeva HS
Clin Endocrinol (Oxf); 2017 Oct; 87(4):313-319. PubMed ID: 28640938
[TBL] [Abstract][Full Text] [Related]
33. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
Diamanti-Kandarakis E; Kandaraki E; Christakou C; Panidis D
Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702
[TBL] [Abstract][Full Text] [Related]
34. Adipose tissue dysfunction in polycystic ovary syndrome.
Villa J; Pratley RE
Curr Diab Rep; 2011 Jun; 11(3):179-84. PubMed ID: 21424395
[TBL] [Abstract][Full Text] [Related]
35. Identification of microRNAs and genes associated with hyperandrogenism in the follicular fluid of women with polycystic ovary syndrome.
Xue Y; Lv J; Xu P; Gu L; Cao J; Xu L; Xue K; Li Q
J Cell Biochem; 2018 May; 119(5):3913-3921. PubMed ID: 29193229
[TBL] [Abstract][Full Text] [Related]
36. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome.
Vryonidou A; Papatheodorou A; Tavridou A; Terzi T; Loi V; Vatalas IA; Batakis N; Phenekos C; Dionyssiou-Asteriou A
J Clin Endocrinol Metab; 2005 May; 90(5):2740-6. PubMed ID: 15741256
[TBL] [Abstract][Full Text] [Related]
37. The link between polycystic ovary syndrome and both Type 1 and Type 2 diabetes mellitus: what do we know today?
Barber TM; Franks S
Womens Health (Lond); 2012 Mar; 8(2):147-54. PubMed ID: 22375718
[TBL] [Abstract][Full Text] [Related]
38. A Dietary Medium-Chain Fatty Acid, Decanoic Acid, Inhibits Recruitment of Nur77 to the HSD3B2 Promoter In Vitro and Reverses Endocrine and Metabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.
Lee BH; Indran IR; Tan HM; Li Y; Zhang Z; Li J; Yong EL
Endocrinology; 2016 Jan; 157(1):382-94. PubMed ID: 26465200
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic beta-cells dysfunction in polycystic ovary syndrome.
Diamanti-Kandarakis E; Xyrafis X; Boutzios G; Christakou C
Panminerva Med; 2008 Dec; 50(4):315-25. PubMed ID: 19078872
[TBL] [Abstract][Full Text] [Related]
40. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
Nardo LG; Patchava S; Laing I
Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
